Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozurdex monotherapy for non-infectious uveitis
NCT05101928Phase 4Withdrawn
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Nov 2021
- Primary completion
- Jan 2025
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ozurdex in intermediate uveitis (IU), posterior uveitis, panuveitis, sponsored by Ottawa Hospital Research Institute. Planned start Nov 2021; status: withdrawn.
02
Drugs
ozurdex
03
Conditions
intermediate uveitis (IU)posterior uveitispanuveitis
Beyond the preview
Go deeper on NCT05101928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05101928.